期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 175, 期 1, 页码 43-54出版社
WILEY
DOI: 10.1111/bjh.14177
关键词
Ofatumumab; CHOP; TP53; Richter syndrome; Chronic lymphocytic leukaemia
类别
资金
- Oxford Partnership Comprehensive Biomedical Research Centre
- Department of Health National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme
- National Institute for Health Research, through the National Cancer Research Network
- Julian Starmer-Smith lymphoma fund
- National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme
- Cancer Research UK [16895] Funding Source: researchfish
Richter syndrome (RS) is associated with chemotherapy resistance and a poor historical median overall survival (OS) of 8-10months. We conducted a phase II trial of standard CHOP-21 (cyclophosphamide, doxorubicin, vincristine, prednisolone every 21d) with ofatumumab induction (Cycle 1: 300mg day 1, 1000mg day 8, 1000mg day 15; Cycles 2-6: 1000mg day 1) (CHOP-O) followed by 12months ofatumumab maintenance (1000mg given 8-weekly for up to six cycles). Forty-three patients were recruited of whom 37 were evaluable. Seventy-three per cent were aged >60years. Over half of the patients received a fludarabine and cyclophosphamide-based regimen as prior CLL treatment. The overall response rate was 46% (complete response 27%, partial response 19%) at six cycles. The median progression-free survival was 62months (95% confidence interval [CI] 49-140months) and median OS was 114months (95% CI 64-256months). Treatment-naive and TP53-intact patients had improved outcomes. Fifteen episodes of neutropenic fever and 46 non-neutropenic infections were observed. There were no treatment-related deaths. Seven patients received platinum-containing salvage at progression, with only one patient obtaining an adequate response to proceed to allogeneic transplantation. CHOP-O with ofatumumab maintenance provides minimal benefit beyond CHOP plus rutuximab. Standard immunochemotherapy for RS remains wholly inadequate for unselected RS. Multinational trials incorporating novel agents are urgently needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据